Evidence map›Paper›PMID 35416374›Full record

Trial reportHead & neck2022

Randomized trial of laryngeal organ preservation evaluating two cycles of induction chemotherapy with platinum, docetaxel, and a novel Bcl-xL inhibitor.

Paul L Swiecicki, Emily Bellile, Keith Casper, Steven Bennett Chinn, Aleksandar F Dragovic, Shruti Jolly, Robbi Kupfer, Kelly M Malloy, Michelle Lynn Mierzwa, Andrew G Shuman and 9 more

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Head & neck, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Prognostic Value of Bcl-xL in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology · 2026
    Pooled it
  2. Targeting protein-protein interactions in the BCL-2 family: opportunities for precision oncology.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  3. BCL-2 and BCL-xL in Cancer: Regulation, Function, and Therapeutic Targeting.International journal of molecular sciences · 2026
    Review
  4. Article
  5. Review
  6. Bcl-2 pathway inhibition in solid tumors: a review of clinical trials.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 1 institution in 1 country.

Paul L SwiecickiDepartment of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan, USA.ORCID 0000-0003-2286-3555
Emily BellileDepartment of Biostatistics, University of Michigan, Ann Arbor, Michigan, USA.
Keith CasperRogel Cancer Center, University of Michigan, Ann Arbor, Michigan, USA.
Steven Bennett ChinnRogel Cancer Center, University of Michigan, Ann Arbor, Michigan, USA.
Aleksandar F DragovicRogel Cancer Center, University of Michigan, Ann Arbor, Michigan, USA.
Shruti JollyRogel Cancer Center, University of Michigan, Ann Arbor, Michigan, USA.
Robbi KupferRogel Cancer Center, University of Michigan, Ann Arbor, Michigan, USA.
Kelly M MalloyRogel Cancer Center, University of Michigan, Ann Arbor, Michigan, USA.
Michelle Lynn MierzwaRogel Cancer Center, University of Michigan, Ann Arbor, Michigan, USA.
Andrew G ShumanRogel Cancer Center, University of Michigan, Ann Arbor, Michigan, USA.ORCID 0000-0002-9305-7860
Matthew E SpectorRogel Cancer Center, University of Michigan, Ann Arbor, Michigan, USA.ORCID 0000-0001-7646-6075
Ashok SrinivasanDepartment of Radiology, University of Michigan, Ann Arbor, Michigan, USA.
Chaz StuckenRogel Cancer Center, University of Michigan, Ann Arbor, Michigan, USA.
Carol Rossier BradfordRogel Cancer Center, University of Michigan, Ann Arbor, Michigan, USA.ORCID 0000-0002-2768-4532
Avraham EisbruchRogel Cancer Center, University of Michigan, Ann Arbor, Michigan, USA.
Thomas E CareyRogel Cancer Center, University of Michigan, Ann Arbor, Michigan, USA.
Mark E PrinceRogel Cancer Center, University of Michigan, Ann Arbor, Michigan, USA.ORCID 0000-0002-1120-9008
Gregory T WolfRogel Cancer Center, University of Michigan, Ann Arbor, Michigan, USA.
Francis P WordenDepartment of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan, USA.
University of Michigan · US

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Alexey I Nesvizhskii · 1988 to 2026
$178.2M
Therapeutic Potential and Mechanism of Action of Potent Small Molecule InhibitorsP50CA097248 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI WOLF, GREGORY T · 2002 to 2013
$25.3M
Advanced Research Training in OtolaryngologyT32DC005356 · NIDCD · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CORFAS, GABRIEL · 2002 to 2021
$3.5M
NCI NIH HHS P30 CA046592NCI NIH HHS P3O CA046592NCI NIH HHS P50 CA097248NCI NIH HHS P50CA097248NIDCD NIH HHS T32 DC005356
6 · The paper itself

Abstract

backgroundSingle cycle induction chemotherapy (IC) with platinum and 5-flurouracil (PF) and treatment based on clinical response predicts organ preservation in laryngeal cancer. Other agents offer intriguing alternatives with potentially increased ease of administration, reduced risk for severe toxicities, and increased platinum sensitivity.

methodsWe report the results of a phase II bioselection trial in advanced resectable laryngeal cancer utilizing an IC regimen of two cycles of platinum plus docetaxel (TP) with a Bcl-2 inhibitor. The primary endpoint was organ preservation rate at 12 weeks post chemoradiation.

resultsFifty-four patients were enrolled. Response to IC was 72%. The organ preservation rate was 59% with a laryngectomy free survival of 46%. Induction related grade ≥3 toxicities were observed in 56% of patients with two grade 5 events.

conclusionsTwo cycles of TP IC plus a Bcl-2 inhibitor did not improve laryngeal preservation compared to a single cycle of PF.

Indexed as

Antineoplastic AgentsLaryngeal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsCisplatinDocetaxelFluorouracilHumansInduction ChemotherapyOrgan PreservationPlatinumProto-Oncogene Proteins c-bcl-2Antineoplastic AgentsCisplatinDocetaxelFluorouracilPlatinumProto-Oncogene Proteins c-bcl-2chemoradiationinduction chemotherapylaryngeal cancerneoadjuvant chemotherapyorgan preservation

Identifiers

PMID35416374
PMCPMC10681682
OpenAlexW4225582304

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.